

## **Dr. Mikael Horissian's Experience with APT-T3X in Patients with Hidradenitis Suppurativa**

As a dermatologist with extensive experience in managing hidradenitis suppurativa, I have observed that APT-T3X offers meaningful benefits for many of my patients with hidradenitis suppurativa. In my practice, there have been patients who experienced rapid improvement in pain, decreased drainage, and even less frequent flares with its use.


Many of my patients have sought to avoid undergoing long-term oral antibiotic therapy due to the risks associated with it. The topical application of APT-T3X, which contains 3% tetracycline, allows for application directly into affected areas and can be a valuable option for these patients with hidradenitis suppurativa, giving them an alternative to try that has been used in other medical settings for years. Specifically, the formulation's dual-action mechanism has been used to prevent infection, treat biofilms, and expedite healing in the wound care setting for over 8 years. Conveniently for patients, APT-T3X is available without a prescription.

It is important to stress that, although my clinical experience has been positive, APT-T3X has not yet been formally studied or approved for the treatment of hidradenitis suppurativa. These observations are based on my personal experience and are not a substitute for data derived from controlled clinical trials. Patients considering this treatment should consult with their healthcare providers to determine whether it is appropriate for their individual circumstances.

I support continued research into the use of topical agents like APT-T3X for hidradenitis suppurativa, and I am encouraged by its potential role in expanding our therapeutic options for this challenging condition.

*Mikael Horissian MD*

*Dr. Mikael Horissian*  
Dermatologist





Dear Doctor,

Enclosed are detailed instructions regarding the utilization of the APTT3X™ formulation for patients diagnosed with Hidradenitis Suppurativa (HS). These guidelines are intended to provide insight into the application of APTT3X™ for HS patients. However, it's crucial to note that the attending medical professional may exercise discretion in modifying these guidelines according to the patient's individual needs.

Points for Patient Compliance:

The APTT3X™ formulation exhibits a color ranging from yellow to dark yellow and has the potential to stain fabric. Therefore, it's advisable to utilize non-absorptive materials when bandaging to reduce APTT3X™ absorption from the site of application. Moreover, bandaging should be minimized to ensure patient accessibility to affected areas. To prevent skin contact, application may be conducted using exam gloves or finger cots.

Recommendations for Treatment:

1. Early Lesion Development:

- Apply 2-3 drops to the area displaying initial signs of HS lesion development, such as inflammation or increased sensitivity.
- Ensure application over and around the margin of the lesion.
- Administer treatment every 12 hours for the initial 5-7 days, followed by daily application until the lesion resolves.

2. Open/Draining Lesions and Fistulous Tracts associated with HS:

- Apply 2 to 4 drops (depending on lesion size) and gently massage the formulation into the affected area for 10-15 seconds.
- Extend the application beyond the lesion margins by approximately ½"-1" onto normal skin.
- Administer treatment every 12 hours for the first 5-7 days, followed by daily application until the lesion resolves.

3. Post-Surgical Intervention (deroofing, incisional and drainage, excisional) for HS Lesions:

- Prior to closure, generously apply the formulation to the surgical site to mitigate infections and biofilm development.
- Post-surgical application should entail 2 to 4 drops (depending on lesion size), gently massaged into the incision or open lesion areas for 10-15 seconds.
- Extend the application beyond the lesion margins by about ½"-1" onto normal skin.
- Administer treatment every 12 hours for the initial 5-7 days, followed by daily application until the lesion resolves.

These guidelines aim to assist in the effective use of the APTT3X™ formulation in managing HS, but it's essential for the attending medical professional to adapt these instructions in accordance with the patient's specific requirements.

Sincerely,

Brian Huber

CEO/President

PFTH, LLC